|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
This literature review aimed to identify studies examining single-nucleotide polymorphisms of the oxytocin (OXT) and arginine vasopressin (AVP) receptor genes and their differential effects on social cognitive dysfunction in the development of ASD.
|
31214061 |
2019 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a double-blind, randomized, placebo-controlled, parallel study design, we tested the efficacy and tolerability of a 4-week intranasal AVP daily treatment in 30 children with ASD.
|
31043522 |
2019 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that AVP and its signaling pathway warrant consideration in future research studies investigating new targets for diagnostics and drug development in ASD.
|
29720452 |
2018 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Review of Oxytocin and Arginine-Vasopressin Receptors and Their Modulation of Autism Spectrum Disorder.
|
29487501 |
2018 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further discuss implications for OXT/AVP-related pharmacological interventions to alleviate social deficits in ASD in the future.
|
28551755 |
2017 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous results suggest that OXT and arginine vasopressin (AVP) may play a role in the etiopathogenesis of ASD.
|
27974283 |
2017 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
(3) The degree of negative FC between left amygdala and left supramarginal gyrus was associated with a lowering of the circulating AVP concentration in boys with ASD.
|
28258508 |
2017 |
|
Autism Spectrum Disorders
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed an association study between ASD and polymorphisms in the <i>AVPR1A</i> promoter region in the Korean population using a family-based association test (FBAT).
|
28808521 |
2017 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
As far as we know, there is no comprehensive review of the roles of the OXT and AVP systems in the development of ASD from the genetic aspect.
|
28283809 |
2017 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review how the OT and AVP systems have been investigated in Autism Spectrum Disorder (ASD), Prader-Willi Syndrome (PWS), Williams Syndrome (WS) and Fragile X syndrome (FXS).
|
24462936 |
2014 |
|
Autism Spectrum Disorders
|
0.100 |
Biomarker
|
disease |
BEFREE |
Following a short illustration of several major topics in ASD biology we will (a) briefly describe the oxytocinergic and vasopressinergic systems in the brain, (b) discuss a few compelling cases manifesting the involvement of OT and AVP in mammalian social behavior, (c) describe data supporting the role of these peptides in human social cognition and behavior, and (d) discuss the possibility of the involvement of OT and AVP in ASD etiology, as well as the prospect of using these peptides as a treatment for ASD patients.
|
21150165 |
2010 |
|
Autism Spectrum Disorders
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined three microsatellites in the arginine vasopressin 1a receptor gene (AVPR1a), two in the promoter region (RS1 and RS3) and an intronic microsatellite (AVR), for association with autism as well as scores on the Vineland Adaptive Behavior Scale (VABS), the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Scale-Generic (ADOS-G), measures that are widely used to diagnose autism spectrum disorders.
|
16520824 |
2006 |